CN117897171A

CN117897171A - Vaccine for preventing African swine fever comprising antigen protein derived from African swine fever virus

Info

Publication number: CN117897171A
Application number: CN202280058561.XA
Authority: CN
Inventors: 姜享注; 崔宝化; 孙恩珠
Original assignee: Bioapplications Inc
Current assignee: Bioapplications Inc
Priority date: 2021-08-27
Filing date: 2022-08-12
Publication date: 2024-04-16

Abstract

The present invention relates to a recombinant vector comprising a nucleotide sequence of african swine fever virus antigen protein Lectin (Lectin), CD2v, p72, p54, p30, p15, p35, E199L and/or F317L, a transgenic organism transformed with the above recombinant vector, a vaccine composition for preventing african swine fever comprising african swine fever virus Lectin isolated from the above transgenic organism, CD2v, p72, p54, p30, p15, p35, E199L and/or F317L antigen protein as an active ingredient, and the like.

Description

Vaccine for preventing African swine fever comprising antigen protein derived from African swine fever virus

Technical Field

The present invention relates to a vaccine for preventing african swine fever and the like comprising an antigen protein derived from african swine fever virus (African swine fever virus) as an active ingredient.

The present invention claims priority from korean patent application No. 10-2021-014014 filed on month 27 of 2021 and No. 10-2022-0097525 filed on month 4 of 2022, the entire contents of which are incorporated herein by reference in the specification and the drawings.

Background

African swine fever (African swine fever, ASF) is swine fever caused by African swine fever virus (African swine fever virus, ASFV) infected with African swine fever virus (Asfarviridae), and after being reported for the first time in Kennel in 1921, the African swine fever is mainly reported in the Saharan south area, and after 2007, the African swine fever has been expanded to African areas such as George, amania and African, along the coast of the black sea. In particular, about half of the global pig raising amount is occupied in China, about 700 thousands of pigs are formally killed by ASF in the first explosion in 2018, about 2 hundred million pigs are actually estimated to be killed, and huge property loss is caused. ASF onset was controlled all the time thereafter, but ASF cases were reported again in the north regions of china in the very beginning of the year. ASF epidemic is also reoccurring in vietnam, and by 5 months of this year, about 36000 pigs were killed in 2021 and over 600 tens of thousands of pigs were killed in 2019, but new cases were continuously reported nationwide in vietnam. Furthermore, malaysia with no ill cases was also first detected for ASF virus at the end of 2 months of the year.

In korea, pig farmers in the state of hillside reported ASF epidemic situations for the first time in 2019, after which the kyoto and the river were brought to report on the infection cases successively. In the wild boar, about 9 months in 2020, it was confirmed that the city county of african swine fever was 9 places such as hilly city, chuanchuanjun city, banchuanjun city, and jun city in the kyo, the jun, the chuanchuanjun city, yang Koujun, the lin-hoof county, and the gakucheng county. Of these, jiang Yuandao Hua Chuan is up to 285, followed by 282 in the city of ripple, county, kyuga, and 98 immediately thereafter. Therefore, in order to prevent ASF from spreading, a wide area fence was set up, and active wild boar capture and epidemic prevention was implemented, and as a result, after infection cases occurred in the pig farm of 10 months Jiang Yuandao Hua Chuan in 2020, no ASFV infection cases were reported for a while, but ASF onset cases were reported again in the pig farm of the last (8 months in 2021) Jiangyuan.

The mortality rate of pigs infected with african swine fever is as high as 100%, and since no vaccine is developed against the disease, it is a high risk infectious disease that needs to be treated immediately after occurrence, and prevention thereof is still a very important problem.

On the other hand, the development of molecular biology and genetic engineering techniques has been well suited for use in the plant field, and efforts have been made to produce useful physiologically active substances from plant bodies. The production of useful substances from plants can significantly reduce the production cost, not only eliminate from the source various pollution sources (viruses, oncogenes, enterotoxins, etc.) which may be produced by conventional methods (methods of synthesizing proteins from animal cells or microorganisms and performing isolation and purification), but also have advantageous advantages in terms of seed management seedlings (seed stock) unlike animal cells or microorganisms in the commercialization stage.

In view of the above, the present inventors have made an effort to develop an antigen for preventing african swine fever, and finally have developed a system capable of efficiently expressing african swine fever virus antigen proteins in plants, and have confirmed that a combination of specific proteins among the antigen proteins can more effectively prevent african swine fever than other ASFV antigen protein combinations, thereby completing the present invention.

Disclosure of Invention

Technical problem

African swine fever virus is a giant double helix DNA virus that replicates in the cytoplasm of infected cells. The virus can continuously infect the genus of the Blackbone ticks (Ornithodoros) of the family of Soft ticks in the natural host pigs, black boars, river boars and the like which act as vehicles under the condition of no disease symptoms while causing high-mortality hemorrhagic fever to pigs. This virus causes the pig to develop fatal hemorrhagic fever, so that early prevention before infection is a very important infectious disease.

The present invention has been made to solve the above-described problems of the prior art and the necessity of prevention of african swine fever, and an object of the present invention is to provide a recombinant antigen protein derived from african swine fever virus, a vaccine composition comprising the same, and the like, wherein not only efficient production using plant bodies can be achieved, but also high immunogenicity (immunogenicity) can be exhibited.

However, the technical problems to be solved by the present invention are not limited to the above-mentioned problems, and other problems not mentioned can be clearly understood by the ordinary skilled person from the following description.

Technical proposal

The present invention provides a vaccine composition for preventing African swine fever, comprising as an active ingredient a combination of antigen proteins of African swine fever virus (African swine fever virus, ASFV), wherein the combination of antigen proteins of ASFV is a combination of at least one selected from the group consisting of Lectin (Lectin), CD2v, p72, p54 and p30 proteins.

However, when the ASFV antigen proteins comprise lectin proteins and CD2v proteins, the ASFV antigen proteins consist of three or more antigen proteins.

In another embodiment of the present invention, the vaccine composition may satisfy one or more characteristics selected from the group consisting of, but not limited to:

(a) The lectin protein comprises the amino acid sequence of SEQ ID NO. 1;

(b) The CD2v protein contains the amino acid sequence of SEQ ID NO. 3;

(c) The p72 protein comprises the amino acid sequence of SEQ ID NO. 5;

(d) The p54 protein comprises the amino acid sequence of SEQ ID NO. 7; and

(e) The p30 protein contains the amino acid sequence of SEQ ID NO. 9.

In still another embodiment of the present invention, the ASFV antigen protein is produced using a recombinant vector, which may include one or more ASFV protein-encoding polynucleotides from the group consisting of, but not limited to:

(a) A lectin-encoding polynucleotide comprising the base sequence represented by SEQ ID NO. 2;

(b) A CD2 v-encoding polynucleotide comprising a base sequence represented by SEQ ID NO. 4;

(c) A p 72-encoding polynucleotide comprising a base sequence represented by SEQ ID NO. 6;

(d) A p 54-encoding polynucleotide comprising a base sequence represented by SEQ ID NO. 8; and

(e) A p 30-encoding polynucleotide comprising the base sequence represented by SEQ ID NO. 10.

In still another embodiment of the present invention, the recombinant vector may further comprise one or more of the group consisting of, but not limited to:

(a) A polynucleotide encoding NB of SEQ ID NO. 19 or BiP of SEQ ID NO. 21;

(b) A polynucleotide encoding a pFC2 fragment of SEQ ID NO. 27;

(c) A polynucleotide encoding an HDEL peptide of SEQ ID No. 29; and

(d) A polynucleotide encoding the M domain of SEQ ID NO. 23 or the polyhistidine tag (polyhistidine tag) of SEQ ID NO. 25.

In still another embodiment of the present invention, the ASFV antigen protein may be produced in a plant transformed with the recombinant vector, but is not limited thereto.

In still another embodiment of the present invention, the above vaccine composition may further comprise an adjuvant (adjuvant), but is not limited thereto.

In still another embodiment of the present invention, the above-mentioned adjuvant may be mineral oil (mineral oil) or an adjuvant based on emulgen, but is not limited thereto.

Furthermore, the present invention provides a vaccine kit for preventing african swine fever comprising the vaccine composition of the present invention.

Furthermore, the present invention provides a method for preventing, ameliorating and/or treating african swine fever, comprising the step of administering the composition of the present invention (or a combination of one or more proteins selected from the group consisting of lectin, CD2v, p72, p54 and p30 proteins) to animals other than humans.

Furthermore, the present invention provides a use of the above composition for preventing, ameliorating and/or treating african swine fever.

Furthermore, the invention provides a use of the composition in preparing a vaccine for preventing African swine fever.

The present invention also provides a feed composition for preventing african swine fever, comprising as an active ingredient a combination of african swine fever virus (African swine fever virus, ASFV) antigen proteins, wherein the combination of ASFV antigen proteins is one or more selected from the group consisting of lectin, CD2v, p72, p54 and p30 proteins.

Furthermore, the present invention provides a recombinant vector for expressing an antigen protein of african swine fever virus, comprising: a polynucleotide encoding a p72 protein comprising the amino acid sequence of SEQ ID NO. 5; a polynucleotide encoding a p54 protein comprising the amino acid sequence of SEQ ID NO. 7; a polynucleotide encoding a p15 protein comprising the amino acid sequence of SEQ ID NO. 11; a polynucleotide encoding a p35 protein comprising the amino acid sequence of SEQ ID NO. 13; a polynucleotide encoding an E199L protein comprising the amino acid sequence of SEQ ID NO. 15; or a polynucleotide encoding an F317L protein comprising the amino acid sequence of SEQ ID NO. 17.

The recombinant vector for expressing the antigen protein of the African swine fever virus is expressed in a plant body.

In one embodiment of the present invention, the recombinant vector may satisfy one or more characteristics selected from the group consisting of, but not limited to:

(a) The polynucleotide encoding the p72 protein comprises a base sequence represented by SEQ ID NO. 6;

(b) The polynucleotide encoding the p54 protein comprises a base sequence represented by SEQ ID NO. 8;

(c) The polynucleotide encoding the p15 protein comprises a base sequence represented by SEQ ID NO. 12;

(d) The polynucleotide encoding the p35 protein comprises a base sequence represented by SEQ ID NO. 14;

(e) The polynucleotide encoding the E199L protein comprises a base sequence represented by SEQ ID NO. 16; and

(f) The polynucleotide encoding the F317L protein comprises the base sequence represented by SEQ ID NO. 18.

In another embodiment of the present invention, the above recombinant vector may further comprise a polynucleotide encoding a novel chaperone binding protein (new chaperone binding protein, NB) of SEQ ID NO. 19 or a polynucleotide encoding a chaperone binding protein (chaperone binding protein, biP) of SEQ ID NO. 21, but is not limited thereto.

In still another embodiment of the present invention, the polynucleotide encoding the NB or BiP may be located in the 5' -terminal direction of the polynucleotide encoding the p72 protein, the p54 protein, the p15 protein, the p35 protein, the E199L protein or the F317L protein, but is not limited thereto.

In still another embodiment of the present invention, the recombinant vector may further comprise a polynucleotide encoding a pFC2 (pore Fc) fragment of SEQ ID NO. 27, but is not limited thereto.

In still another embodiment of the present invention, the polynucleotide encoding the above-described pFc2 fragment may be located at the 3' -end of the polynucleotide encoding the above-described p72 protein, p54 protein, p15 protein, p35 protein, E199L protein or F317L protein, but is not limited thereto.

In still another embodiment of the present invention, the above recombinant vector may further comprise a polynucleotide encoding an HDEL (His-Asp-Glu-Leu) peptide of SEQ ID NO. 29, but is not limited thereto.

In still another embodiment of the present invention, the polynucleotide encoding the above HDEL peptide may be located at the 3' -end of the polynucleotide encoding the above p72 protein, p54 protein, p15 protein, p35 protein, E199L protein or F317L protein, but is not limited thereto.

In yet another embodiment of the present invention, the above recombinant vector may further comprise a polynucleotide encoding NB of SEQ ID NO. 19 or BiP of SEQ ID NO. 21; a polynucleotide encoding a pFC2 fragment of SEQ ID NO. 27; and a polynucleotide encoding the HDEL peptide of SEQ ID NO. 29, but is not limited thereto.

In another embodiment of the present invention, the recombinant vector is connected to: a polynucleotide encoding NB or BiP; polynucleotides encoding a p72 protein, a p54 protein, a p15 protein, a p35 protein, an E199L protein, or an F317L protein; a polynucleotide encoding a pFc2 fragment; and polynucleotides encoding HDEL peptides, but are not limited thereto.

Furthermore, the present invention provides a transgenic organism transformed with the recombinant vector of the present invention.

In one embodiment of the present invention, the transgenic organism may be a plant, but is not limited thereto.

In addition, the invention provides a preparation method of the recombinant African swine fever virus antigen protein, which comprises the following steps:

step (S1), transforming the recombinant vector of the present invention into a plant; and

and (S2) isolating and purifying the recombinant antigen protein from the plant body or the culture medium.

In one embodiment of the present invention, the above NB-encoding polynucleotide may comprise the base sequence represented by SEQ ID NO. 20; the above-mentioned BiP-encoding polynucleotide may comprise a base sequence represented by SEQ ID NO. 22; the pFC 2-encoding polynucleotide may comprise the base sequence represented by SEQ ID NO. 28; the HDEL-encoding polynucleotide may include the base sequence represented by SEQ ID NO. 30, but is not limited thereto.

Effects of the invention

Proteins for preventing viral diseases including african swine fever, in particular, antigens cannot be produced using bacteria, mainly animal cells, due to problems such as folding (folding) of proteins, glycation (glycation) and the like. However, in the vaccine production method using animal cells, the equipment expansion for mass production requires a large cost, and thus, the production is not easy, and in most cases, the price of the antigen is high. In addition, the antigen prepared by using animal cells has a disadvantage of being difficult to store and having a high possibility of being contaminated with viruses of the animal that can be infected. However, the present invention compensates for the disadvantages with plants. That is, unlike animal cells, plant cells have a very low possibility of being contaminated with viruses that can infect animals, can be mass-produced at any time as long as the cultivated area is ensured, and can be preserved for a long period of time by the plant body, so that inexpensive antigens can be stably produced.

The recombinant african swine fever virus antigen protein of the present invention can be efficiently expressed not only in plants but also has high Water solubility (Water solubility) and thus is easy to isolate and purify, and also functions as an antigen in vivo and shows high immunogenicity, thus being useful as a novel african swine fever virus vaccine composition. In particular, the present inventors confirmed through challenge vaccination experiments that vaccine compositions comprising the 5 antigen proteins (lectin, CD2v, p54, p72 and p 30) of the present invention have a very remarkable effect of preventing african swine fever as compared to vaccine compositions further comprising other antigen proteins (p 15, p35, E199L, F317L, etc.), and thus have a promising prospect of using the recombinant vector and vaccine composition of the present invention in the livestock industry and the like.

Drawings

FIG. 1 is a diagram showing the genetic arrangement of lectin, CD2v, p72, p54, p30, p15, p35, E199L and F317L antigen proteins for expressing ASFV in plant bodies of the present invention.

FIG. 2 shows the results of isolation and purification of lectin antigen proteins of ASFV, followed by electrophoresis, confirmed by Coomassie blue staining.

FIG. 3 shows the results of the purification and isolation of the CD2v antigen protein of ASFV and the electrophoresis, and the confirmation by Coomassie blue staining method.

FIG. 4a is a graph showing the bands obtained by performing western blotting to confirm the expression of the P72 antigen protein of ASFV (DT: total sample before Debris removal (Debris Total), T: total sample after Debris removal (Total extract), P: particle (Pellet) fractionation, FT: flow path (Flow through) fractionation, and the like).

FIG. 4b shows the results of separating and purifying the p72 antigen protein of ASFV, subjecting the protein solution before and after concentration to electrophoresis, and confirming by Coomassie blue staining method (left: p72 protein detection result before concentration; right: p72 protein detection result after concentration).

FIG. 5a is a band diagram obtained by performing protein imprinting in order to confirm the expression of p54 antigen protein of ASFV.

FIG. 5b shows the results of separating and purifying the p54 antigen protein of ASFV, subjecting the protein solution before and after concentration to electrophoresis, and confirming by Coomassie blue staining method (left: p54 protein detection result before concentration; right: p54 protein detection result after concentration).

FIG. 6 shows the results of the purification and isolation of the p30 antigen protein of ASFV and the electrophoresis, and the confirmation by Coomassie blue staining method.

FIG. 7a is a band diagram obtained by performing protein imprinting in order to confirm the expression of the p15 antigen protein of ASFV.

FIG. 7b shows the results of the purification and isolation of the p15 antigen protein of ASFV and the electrophoresis, the confirmation by Coomassie blue staining method.

FIG. 8 shows the results of the purification and isolation of the p35 antigen protein of ASFV and the electrophoresis, and the confirmation by Coomassie blue staining method.

FIG. 9a is a band diagram obtained by performing protein imprinting for confirming the expression of E199L antigen protein of ASFV.

FIG. 9b shows the results of separating and purifying E199L antigen protein of ASFV, subjecting the protein solution before and after concentration to electrophoresis, and confirming by Coomassie blue staining method (left: E199L protein detection result before concentration; right: E199L protein detection result after concentration).

FIG. 10a is a band diagram obtained by performing protein imprinting in order to confirm the expression of F317L antigen protein of ASFV extracted from 100g or 1kg of leaves of Nicotiana banbury (upper end: F317L protein detection result extracted from 100g of leaves; lower end: F317L protein detection result extracted from 1kg of leaves).

FIG. 10b shows the results of separating and purifying F317L protein of ASFV extracted from 100g or 1kg leaves of Nicotiana tabacum and performing electrophoresis, which were confirmed by Coomassie blue staining method (left: F317L protein detection result extracted from 100g leaves; right: F317L protein detection result extracted from 1kg leaves).

FIG. 11 shows results of challenge vaccination experiments performed on pigs after treatment with 5 antigen vaccines (lectin, CD2v, p54, p72 and p30 combinations), 9 antigen vaccines (lectin, CD2v, p54, p72, p30, p15, p35, E199L and F317L combinations) or PBS according to the present invention to confirm body temperature and survival rate of pigs as a function of time.

FIG. 12 is a graph showing the results of challenge vaccination experiments performed on pigs after treatment with 5 antigen vaccines, 9 antigen vaccines or PBS according to the present invention to determine virus (Viremia) levels in blood of pigs over time.

FIG. 13 shows the gene sequence (upper end) and amino acid sequence (lower end) for expressing a lectin recombinant protein according to an embodiment of the present invention.

FIG. 14 shows the gene sequence (upper end) and amino acid sequence (lower end) for expressing a CD2v recombinant protein according to an embodiment of the present invention.

FIG. 15 shows the gene sequence (upper end) and amino acid sequence (lower end) for expressing the p72 recombinant protein according to an embodiment of the present invention.

FIG. 16 shows the gene sequence (upper end) and amino acid sequence (lower end) for expressing a p54 recombinant protein according to an embodiment of the present invention.

FIG. 17 shows the gene sequence (upper end) and amino acid sequence (lower end) for expressing the p30 recombinant protein according to an embodiment of the present invention.

FIG. 18 shows the gene sequence (upper end) and amino acid sequence (lower end) for expressing a p15 recombinant protein according to an embodiment of the present invention.

FIG. 19 shows the gene sequence (upper end) and amino acid sequence (lower end) for expressing a p35 recombinant protein according to an embodiment of the present invention.

FIG. 20 shows the gene sequence (upper end) and amino acid sequence (lower end) for expressing E199L recombinant protein according to an embodiment of the present invention.

FIG. 21 shows the gene sequence (upper end) and amino acid sequence (lower end) for expressing F317L recombinant protein according to an embodiment of the present invention.

FIG. 22 shows the results of measuring the levels of anti-p 30 antibodies on days 0, 7, 14, 21, 28 and 35 after administration of 5 antigen vaccines (lectin, CD2v, p54, p72 and p30 combination; "Vax grp 1"), 9 antigen vaccines (lectin, CD2v, p54, p72, p30, p15, p35, E199L and F317L combination; "Vax grp 2") or PBS ("PBS") of the present invention to pigs.

Detailed Description

Unless defined otherwise, all technical and scientific terms used in this specification have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used in the present specification is well known and commonly employed in the art.

The present inventors confirmed that each of the above-mentioned ASFV antigen proteins having high immunogenicity was efficiently produced and isolated from a plant using five antigen protein lectins of african swine fever virus (African swine fever virus, ASFV), and genes of CD2v, p72, p54, p30, p15, p35, E199L and F317L. Therefore, the African swine fever virus antigen protein of the present invention can be stably and efficiently mass-produced, and thus, an inexpensive and stable African swine fever virus vaccine can be provided. The present inventors have also confirmed that when a vaccine composition containing five antigen proteins (including lectin, CD2v, p72, p54, and p 30) is administered to pigs, an excellent african swine fever prevention effect is exhibited, and that the effect is more remarkable than a vaccine composition further containing other ASFV antigen proteins such as p15, p35, E199L, and F317L. That is, the present invention has been made in view of the above-described problems, and it is an object of the present invention to find an optimal antigen protein combination (lectin, CD2v, p72, p54 and p 30) that can achieve a more remarkable african swine fever prevention effect than the prior art.

Accordingly, an object of the present invention is to provide a recombinant vector for expressing an ASFV antigen protein comprising a combination of an african swine fever virus (African swine fever virus, ASFV) protein-encoding polynucleotide, the combination of the ASFV protein-encoding polynucleotide being one or more selected from the group consisting of:

A polynucleotide encoding a lectin protein comprising the amino acid sequence of SEQ ID NO. 1;

a polynucleotide encoding a CD2v protein comprising the amino acid sequence of SEQ ID No. 3;

a polynucleotide encoding a p72 protein comprising the amino acid sequence of SEQ ID NO. 5;

a polynucleotide encoding a p54 protein comprising the amino acid sequence of SEQ ID NO. 7;

a polynucleotide encoding a p30 protein comprising the amino acid sequence of SEQ ID NO. 9;

a polynucleotide encoding a p15 protein comprising the amino acid sequence of SEQ ID NO. 11;

a polynucleotide encoding a p35 protein comprising the amino acid sequence of SEQ ID NO. 13;

a polynucleotide encoding an E199L protein comprising the amino acid sequence of SEQ ID NO. 15; and

a polynucleotide encoding an F317L protein comprising the amino acid sequence of SEQ ID No. 17.

More preferably, the present invention is directed to a recombinant vector for expressing an ASFV antigen protein comprising a combination of an african swine fever virus (African swine fever virus, ASFV) protein-encoding polynucleotide, which is a combination of one or more selected from the group consisting of:

a polynucleotide encoding a p54 protein comprising the amino acid sequence of SEQ ID NO. 7; and

a polynucleotide encoding a p30 protein comprising the amino acid sequence of SEQ ID No. 9.

In the recombinant vector, the arrangement order of the polynucleotides is not limited.

In the present invention, "African swine fever virus (African swine fever virus)" is a DNA virus of about 200nm of the genus African swine fever virus (Asfarviridae) belonging to the family African swine fever virus, and is a causative agent of African swine fever (African swine fever, ASF). ASFV causes a natural host pig, black boar, river boar, etc. to continuously infect the genus Chlopyrifos (Ornithiodoros) of the family Soft ticks, which causes fatal hemorrhagic fever.

Preferably, the recombinant vector of the present invention is characterized by comprising the above-mentioned five ASFV proteins (lectin, CD2v, p72, p54 and p 30) encoding-polynucleotides, and not comprising the ASFV protein-encoding polynucleotides in addition thereto. More preferably, the recombinant vector of the present invention is characterized by not comprising a polynucleotide encoding an antigen protein p15, p35, E199L or F317L of ASFV.

The lectin antigen protein described above comprises the amino acid sequence of SEQ ID NO. 1 or is encoded by a polynucleotide comprising the base sequence of SEQ ID NO. 2, most preferably consists of the amino acid sequence of SEQ ID NO. 1 or is encoded by a polynucleotide consisting of the base sequence of SEQ ID NO. 2, but is not limited thereto. Preferably, the lectin protein of the invention comprises a transmembrane domain, or is a lectin protein with a transmembrane domain removed.

Specifically, the polynucleotide encoding a lectin protein described above may be composed of the base sequence represented by SEQ ID NO. 2, but is not limited thereto, and variants of the base sequence described above are included in the scope of the present invention. The nucleic acid molecule of the base sequence represented by SEQ ID NO. 2 of the present invention is a concept covering functional equivalents of nucleic acid molecules constituting the same, for example, variants (variants) in which a part of the base sequence of a nucleic acid molecule is modified by deletion (substitution), substitution (insertion) or insertion (insertion), but functionally has the same function as a nucleic acid molecule. Specifically, the above polynucleotide encoding a lectin protein may contain a base sequence having a sequence homology of 70% or more, more preferably 80% or more, still more preferably 90% or more, most preferably 95% or more, respectively, with the base sequence represented by SEQ ID NO. 2. For example, polynucleotides having 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% sequence homology are included. "percent sequence homology" to a polynucleotide is confirmed by comparing two optimally aligned sequences to a comparison region, a portion of which may have additions or deletions (i.e., gaps) as compared to a reference sequence (excluding additions or deletions) for optimal alignment of the two sequences.

Further, the above-mentioned CD2v antigen protein comprises the amino acid sequence of SEQ ID NO. 3 or is encoded by a polynucleotide comprising the base sequence of SEQ ID NO. 4, most preferably consists of the amino acid sequence of SEQ ID NO. 3 or is encoded by a polynucleotide consisting of the base sequence of SEQ ID NO. 4, but is not limited thereto. That is, the above polynucleotide encoding a CD2v protein may comprise a base sequence having a sequence homology of 70% or more, more preferably 80% or more, still more preferably 90% or more, most preferably 95% or more, with the base sequence represented by SEQ ID NO. 4, respectively. Preferably, the CD2v of the invention comprises a transmembrane domain (transmembrane domain, TMD) of a CD2v protein, or may be a CD2v protein from which the transmembrane domain has been removed, preferably may be the N-terminal part of the transmembrane domain from the CD2v protein.

Furthermore, the above p72 antigen protein comprises the amino acid sequence of SEQ ID NO. 5 or is encoded by a polynucleotide comprising the base sequence of SEQ ID NO. 6, most preferably consists of the amino acid sequence of SEQ ID NO. 5 or is encoded by a polynucleotide consisting of the base sequence of SEQ ID NO. 6, but is not limited thereto. That is, the above polynucleotide encoding a p72 protein may comprise a base sequence having a sequence homology of 70% or more, more preferably 80% or more, still more preferably 90% or more, most preferably 95% or more, with the base sequence represented by SEQ ID NO. 6, respectively.

Furthermore, the above p54 antigen protein comprises the amino acid sequence of SEQ ID NO. 7, or is encoded by a polynucleotide comprising the base sequence of SEQ ID NO. 8, most preferably consists of the amino acid sequence of SEQ ID NO. 7, or is encoded by a polynucleotide consisting of the base sequence of SEQ ID NO. 8, but is not limited thereto. That is, the above polynucleotide encoding a p54 protein may comprise a base sequence having a sequence homology of 70% or more, more preferably 80% or more, still more preferably 90% or more, most preferably 95% or more, with the base sequence represented by SEQ ID NO. 8, respectively. Preferably, the p54 protein of the invention may be a p54 protein (p 54 dTM) with the transmembrane domain removed. More preferably, the p54 proteins of the invention may comprise a transmembrane domain. Alternatively, the p54 protein may be one in which the transmembrane domain is removed and a linker sequence is inserted in place of it. The above-mentioned connecting sequence can be Gly-Gly-Gly-Gly-Ser.

Furthermore, the above p30 antigen protein comprises the amino acid sequence of SEQ ID NO. 9, or is encoded by a polynucleotide comprising the base sequence of SEQ ID NO. 10, most preferably consists of the amino acid sequence of SEQ ID NO. 9, or is encoded by a polynucleotide consisting of the base sequence of SEQ ID NO. 10, but is not limited thereto. That is, the above polynucleotide encoding a p30 protein may comprise a base sequence having a sequence homology of 70% or more, more preferably 80% or more, still more preferably 90% or more, most preferably 95% or more, with the base sequence represented by SEQ ID NO. 10, respectively.

Furthermore, the above p15, p35, E199L and F317L antigen proteins comprise the amino acid sequence of SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15 or SEQ ID NO. 17, respectively, or are encoded by polynucleotides comprising the base sequences of SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO. 16 or SEQ ID NO. 18, respectively, most preferably consist of the amino acid sequences of SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15 or SEQ ID NO. 17, respectively, or are encoded by polynucleotides comprising the base sequences of SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO. 16 or SEQ ID NO. 18, respectively, but are not limited thereto. That is, the above polynucleotide encoding a p15, p35, E199L or F317L antigen protein may sequentially contain a base sequence having 70% or more, more preferably 80% or more, still more preferably 90% or more, most preferably 95% or more sequence homology with the base sequence represented by SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO. 16 or SEQ ID NO. 18, respectively.

Furthermore, the E199L described above may be transmembrane domain containing, or transmembrane domain excluded.

In the present specification, a polypeptide (or peptide) composed of an amino acid sequence represented by a specific sequence number is a concept covering functional equivalents of a polypeptide molecule constituting the same, for example, a variant in which a part of the amino acid sequence of the polypeptide molecule is modified by deletion, substitution, or insertion, but functionally has the same function as the polypeptide molecule. Specifically, the above-described polypeptide represented by a specific sequence number may contain an amino acid sequence having a sequence homology of 70% or more, more preferably 80% or more, still more preferably 90% or more, most preferably 95% or more, respectively, with an amino acid sequence represented by a corresponding sequence number. For example, the amino acid sequence includes an amino acid sequence having a sequence homology of 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%. "percent sequence homology" to an amino acid sequence is confirmed by comparing two optimally aligned sequences to a comparison region, a portion of which may have additions or deletions (i.e., gaps) as compared to a reference sequence (excluding additions or deletions) for optimal alignment of the two sequences.

The lectin, CD2v, p54, p72, p30, p15, p35, E199L and F317L antigen proteins are antigen proteins of African swine fever virus, and can regulate the immune response mechanism of a host.

The term "polynucleotide" as used in this specification refers to an oligomer or polymer that includes two or more nucleotides or derivatives thereof that are typically linked by phosphodiester bonds, and includes deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Polynucleotides also include, for example, nucleotide analogs, or DNA and RNA derivatives having "backbone" linkages other than phosphodiester linkages, such as phosphotriester linkages, phosphoramidate linkages, phosphorothioate linkages, thioester linkages, or peptide linkages (peptide nucleic acids). Polynucleotides include single-and/or double-stranded polynucleotides, for example, including not only deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), but also analogs of either RNA or DNA.

The term "antigen" as used herein refers to a general term for all substances that cause an immune response in vivo, and is preferably a virus, a compound, a bacterium, pollen, a cancer cell, or a partial peptide or protein thereof, and is not limited as long as it can cause an immune response in vivo.

In one embodiment of the present invention, the recombinant vector may further comprise a polynucleotide encoding NB or BiP signal peptide, a polynucleotide encoding pFC2 fragment of swine, a polynucleotide encoding HDEL peptide, a polynucleotide encoding M domain, a polynucleotide encoding polyhistidine tag, or the like.

In another embodiment of the present invention, the recombinant vector may satisfy one or more of the following characteristics:

(a) The polynucleotide encoding NB or BiP is located in the 5' -terminal direction of the polynucleotide encoding ASFV antigen protein;

(b) The polynucleotide encoding the pFC2 fragment is located at the 3' -end of the polynucleotide encoding the ASFV antigen protein;

(c) The polynucleotide encoding the HDEL peptide is located at the 3' -end of the polynucleotide encoding the ASFV antigen protein; or alternatively

(d) The M domain or polynucleotide encoding a polyhistidine tag is located at the 5 'end or 3' end of the polynucleotide encoding an ASFV antigen protein.

Preferably, the recombinant vector may comprise the polynucleotide encoding NB or BiP; the polynucleotide encoding the pFC2 fragment; and the polynucleotide encoding the HDEL peptide, wherein the sequence of the connection of the genes is not limited, and preferably, the polynucleotide encoding NB or BiP is sequentially connected to the recombinant vector; polynucleotides encoding lectin, CD2v, p72, p54 and/or p30 proteins; a polynucleotide encoding a pFc2 fragment; a polynucleotide encoding an HDEL peptide.

Alternatively, the recombinant vectors may all comprise the polynucleotide encoding NB or BiP described above; the polynucleotide encoding the pFC2 fragment; and the polynucleotide encoding the HDEL peptide, wherein the sequence of the connection of the genes is not limited, and preferably, the polynucleotide encoding NB or BiP is sequentially connected to the recombinant vector; polynucleotides encoding lectin, CD2v, p72, p54, p30, p15, p35, E199L and/or F317L proteins; a polynucleotide encoding a pFc2 fragment; a polynucleotide encoding an HDEL peptide.

Most preferably, the recombinant vectors may all comprise the polynucleotide encoding NB or BiP described above; the polynucleotide encoding the pFC2 fragment; the polynucleotide encoding the HDEL peptide; and M domain or polynucleotide encoding polyhistidine tag, in which case the connection sequence of each gene is not limited, preferably, polynucleotide encoding NB or BiP is connected to the recombinant vector in sequence; an M domain or polyhistidine tag; polynucleotides encoding lectin, CD2v, p72, p54 and/or p30 proteins; a polynucleotide encoding a pFc2 fragment; and a polynucleotide encoding an HDEL peptide, or sequentially linked to a polynucleotide encoding NB or BiP; polynucleotides encoding lectin, CD2v, p72, p54 and/or p30 proteins; an M domain or polyhistidine tag; a polynucleotide encoding a pFc2 fragment; a polynucleotide encoding an HDEL peptide.

Alternatively, the recombinant vectors may all comprise the polynucleotide encoding NB or BiP described above; the polynucleotide encoding the pFC2 fragment; the polynucleotide encoding the HDEL peptide; and M domain or polynucleotide encoding polyhistidine tag, in which case the connection sequence of each gene is not limited, preferably, polynucleotide encoding NB or BiP is connected to the recombinant vector in sequence; an M domain or polyhistidine tag; polynucleotides encoding lectin, CD2v, p72, p54, p30, p15, p35, E199L and/or F317L proteins; a polynucleotide encoding a pFc2 fragment; and a polynucleotide encoding an HDEL peptide, or sequentially linked to a polynucleotide encoding NB or BiP; polynucleotides encoding lectins, CD2v, p72, p54, p30, p15 proteins, p35 proteins, E199L proteins, and/or F317L proteins; an M domain or polyhistidine tag; a polynucleotide encoding a pFc2 fragment; a polynucleotide encoding an HDEL peptide.

In another specific embodiment of the present invention, the polynucleotide encoding a polyhistidine tag is characterized in that it is located only in the 5' -end direction of the polynucleotide encoding a lectin in the ASFV antigen protein gene and/or in the 3' -end direction of the polynucleotide encoding p30, and the M domain is characterized in that it is located only in the 5' -end direction of the polynucleotide encoding CD2v in the ASFV antigen protein gene. In another embodiment, the polynucleotide encoding a pFc2 fragment described above is characterized in that it is not located in the 3' end of the polynucleotide encoding p 30.

In the case of ligation by the sequence described above, that is, in the case where the recombinant vector comprises the expression cassette (expression cassette) shown in the FIG. 1 cleavage map, the recombinant vector of the present invention comprises the base sequence represented by SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49 or SEQ ID NO:50, most preferably, may comprise the base sequence represented by SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49 or SEQ ID NO:50, but has 80% or more, more preferably, 90% or more of the base sequence represented by SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:47, SEQ ID NO:49 or SEQ ID NO:50, respectively. The above-mentioned nucleotide sequences represented by SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 47, SEQ ID NO. 48, SEQ ID NO. 49 and SEQ ID NO. 50 may be contained in respective independent plasmid vectors, and one or more combinations selected from the group consisting of SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 47, SEQ ID NO. 48, SEQ ID NO. 49 and SEQ ID NO. 50 may be contained in a single plasmid vector.

In the present specification, "recombinant vector (recombinant vector)" means a vector capable of expressing a peptide or protein encoded by a heterologous nucleic acid inserted into the vector, preferably, a vector prepared to be capable of expressing a target antigen (ASFV antigen lectin, CD2v, p54, p72, p30, p15, p35, E199L and/or F317L in the present invention). The "vector" refers to any vector for introducing and/or transferring bases into a host cell in vitro, in vitro or in vivo, and may be a replication unit (replicon) that binds to other DNA fragments and replicates the bound fragments, and the "replication unit" refers to any genetic unit (e.g., plasmid, phage, cosmid, chromosome, virus, etc.) that functions as a self-unit of DNA replication in vivo, i.e., can regulate replication by itself. Preferably, the recombinant vector of the invention is characterized in that it is expressed in a plant body.

Preferably, the recombinant vector of the present invention includes a transcription promoter (promoter) for binding to RNA polymerase, an arbitrary sequence for regulating transcription, a sequence encoding a suitable mRNA ribose binding site, a sequence for regulating transcription and completion of reading, a terminator, etc., and more preferably, may further include a polyhistidine tag (an amino acid motif consisting of at least 5 histidine residues), an endoplasmic reticulum signal peptide (endoplasmic reticulum signal peptide, the same meaning as that of the endoplasmic reticulum target sequence) gene, an endoplasmic reticulum residual signal peptide (endoplasmic reticulum retention signal peptide), a cloning site (cloning site), etc., and more preferably, may further include a gene for attaching a tag, a marker gene for screening of transgenic organisms, etc., in addition to an Fc fragment as a tag, etc.

Examples of the above-described genes for the tag may include Avi tag, calmodulin (Calmodulin) tag, polyglutamate tag, E tag, FLAG tag, HA tag, his tag (polyhistidine tag), myc tag, S tag, SBP tag, igG Fc tag, CTB tag, softag 1 tag, softag3 tag, strep tag, TC tag, V5 tag, VSV tag, xpress tag, and the like.

In the present specification, the "Fc fragment" means a part in which only heavy chain (H chain) portions are linked by S-S bond and which does not have an antigen binding site when an immunoglobulin is digested with papain, and the Fc fragment of the present invention is preferably a pig Fc fragment, more preferably a pig Fc fragment (pFC 2) represented by SEQ ID NO:28, but is not limited thereto. Furthermore, in the Fc fragment of the present invention, variants of the base sequence represented by SEQ ID NO. 28 are included in the scope of the present invention. Specifically, the above gene may comprise a base sequence having a sequence homology of 90% or more, more preferably 95% or more, most preferably 98% or more with the base sequence of SEQ ID NO. 28.

The "cloning site" mentioned above refers to each gene inserted in the vector for ligation/discrimination purposes. Preferably, the cloning site may be a sequence represented by "tctaga", a sequence represented by "ggatcc", a sequence represented by "cccggg" or a sequence represented by "gagctc" in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8 and SEQ ID NO:10, but is not limited thereto.

The "endoplasmic reticulum signal peptide (ER signal peptide)" is a signal peptide located at the N-terminus of a protein, which induces a newly synthesized protein to enter the inside of the endoplasmic reticulum (endoplasmic reticulum, ER). The endoplasmic reticulum signal peptide of the present invention is not limited in kind and amino acid sequence as long as it is a plant endoplasmic reticulum signal peptide known to those of ordinary skill, and is preferably selected from the group consisting of novel chaperone binding proteins (New chaperone binding protein, NB) and chaperone binding proteins (chaperone binding protein, biP).

The "NB gene" is preferably a gene comprising the base sequence of SEQ ID NO. 20, most preferably a gene represented by SEQ ID NO. 20, and may have a base sequence having 80% or more, more preferably 90% or more, still more preferably 95% or more sequence homology with the base sequence of SEQ ID NO. 20. The "Bip gene" is preferably a gene comprising the base sequence of SEQ ID NO. 22, and most preferably a gene represented by SEQ ID NO. 22, and may have a base sequence having 80% or more, more preferably 90% or more, still more preferably 95% or more sequence homology with the base sequence of SEQ ID NO. 22. As described above, the NB or BiP gene is used to transfer the expressed recombinant protein to the endoplasmic reticulum, and when the recombinant protein is expressed, a part of the sequence is cut off, only a part of the amino acids remain, or the whole sequence is cut off, and the signal peptide sequence part may not exist.

The "endoplasmic reticulum residual signal peptide (ER retention signal peptide)" is a signal peptide located at the C-terminal end of a protein, and when a protein existing in the inner part of the endoplasmic reticulum runs off to Golgi apparatus (Golgi apparatus) through the secretory pathway, the protein can be returned to the endoplasmic reticulum. The endoplasmic reticulum signal peptide of the present invention is not limited in type and amino acid sequence as long as it is a plant residual endoplasmic reticulum signal peptide known to those of ordinary skill, and is preferably selected from KDEL (Lys-Asp-Glu-Leu) sequence and HDEL sequence.

Most preferably, the amino acid sequence of the ER residual signal peptide may be HDEL (His-Asp-Glu-Leu, amino acid represented by SEQ ID NO: 29) and may be encoded by the base sequence represented by SEQ ID NO: 30. Furthermore, variants of SEQ ID NO. 30 in the endoplasmic reticulum signal peptide of the present invention are included in the scope of the present invention. Specifically, the above gene may comprise a base sequence having a sequence homology of 90% or more, more preferably 95% or more, most preferably 98% or more with the base sequence of SEQ ID NO. 30. The binding site of the endoplasmic reticulum signal peptide is attached (or linked) to the C-terminus of a protein which is expressed or synthesized in a plant cell.

For information on the endoplasmic reticulum signal peptide and endoplasmic reticulum residual signal peptide, reference is made to documents such as US20130295065 and WO 2009158716.

Examples of the above-mentioned marker genes for screening may include herbicide resistance genes such as glyphosate (glyphosate) or glufosinate (phosphinothricin), kanamycin (kanamycin), G418, bleomycin (Bleomycin), hygromycin (hygromycin), chloramphenicol (chloromycetin) antibiotic resistance genes, aadA genes and the like, examples of the above-mentioned promoters include pEMU promoter, MAS promoter, histone promoter, clp promoter, 35S promoter from cauliflower mosaic virus (cauliflower mosaic virus), 19S RNA promoter from cauliflower mosaic virus (cauliflower mosaic virus), plant actin promoter, ubiquitin promoter, cytomegalovirus (CMV) promoter, simian virus 40, SV40 promoter, respiratory syncytial virus (Respiratory syncytial virus), RSV) promoter, elongation factor-1α (Elongation factor-1alpha, EF-1α) promoter, pEMU promoter, MAS promoter, histone promoter, clp promoter, macT (CaMV 35S+MAS; mac promoter 3' terminal nucleotide substitution is T) promoter, etc., examples of the above-mentioned terminator may include nopaline synthase (NOS), rice amylase RAmy 1A terminator, phaseolin terminator, octopine (Octopine) gene terminator of Agrobacterium tumefaciens, rrnB1/B2 terminator of Escherichia coli, HSP18.2 terminator of Arabidopsis thaliana, RD29B terminator of Arabidopsis thaliana, etc., but examples of the above-mentioned promoters or terminators are merely illustrative and not limited thereto.

According to another aspect of the present invention, there is provided a transgenic organism transformed with the recombinant vector described above.

In one embodiment of the present invention, the above transgenic organism is preferably a microorganism such as E.coli, bacillus, salmonella, yeast or the like, an insect cell, an animal cell including a human, an animal such as a mouse, rat, dog, monkey, pig, horse, cow or the like, agrobacterium tumefaciens, a plant or the like, more preferably a food crop including rice, wheat, barley, corn, soybean, potato, red bean, oat and sorghum; vegetable crops, including arabidopsis thaliana, cabbage, radish, capsicum, strawberry, tomato, watermelon, cucumber, cabbage, melon, pumpkin, onion, and carrot; special crops including ginseng, tobacco, cotton, sesame, sugar cane, beet, perilla, peanut and rape; and fruit trees including apple, pear, jujube, peach, grape, citrus, persimmon, prune, apricot and banana; and flowers, including roses, carnation, chrysanthemums, lily and tulips, are not limited as long as they are life bodies that can be transformed with the vector of the present invention. Most preferably, the transgenic organism may be a plant of the genus Nicotiana (Nicotiana).

In the present specification, "transformation" is a generic term for altering the genetic properties of an organism by introducing DNA, and the term "transgenic organism (transgenic organism)" refers to an organism produced by injecting an external gene using a molecular genetic method, preferably to an organism transformed with the recombinant vector of the present invention. The organism is not particularly limited as long as the organism is a living organism such as a microorganism, eukaryotic cell, insect, animal, plant, etc., but is preferably escherichia coli, salmonella, bacillus, yeast, animal cell, mouse, rat, dog, monkey, pig, horse, cow, agrobacterium tumefaciens, plant, etc., but is not limited thereto.

In the present specification, the "plant" may use, without limitation, a plant capable of mass-producing a protein comprising the antigen of the present invention, more specifically, a plant selected from the group consisting of tobacco, arabidopsis thaliana, corn, rice, soybean, rapeseed oil, alfalfa, sunflower, alfalfa, sorghum, wheat, cotton, peanut, tomato, potato, lettuce, and capsicum, preferably tobacco. The tobacco of the present invention is a plant of the genus Nicotiana (Nicotiana genus), and the type thereof is not particularly limited as long as it is capable of overexpressing a protein, and the present invention can be carried out by selecting an appropriate variety depending on the transformation method and the purpose of mass production of the protein. For example, a variety such as ban tobacco l. (Nicotiana benthamiana l.) or general tobacco cv.xanthi (Nicotiana tabacum cv.xanthi) can be used.

The above-described transgenic organisms may be produced using methods such as transformation, transfection, agrobacterium-mediated transformation, gene gun bombardment (particle gun bombardment), ultrasound (sound), electroporation (electric), and polyethylene glycol (PEG) -mediated transformation methods, but the present invention is not limited thereto, and any method capable of injecting the vector of the present invention may be used.

According to another aspect of the present invention, there is provided a recombinant protein for inducing antibodies against african swine fever virus, which is produced using the recombinant vector of the present invention. That is, the present invention provides recombinant antigen proteins of lectin, CD2v, p54, p72, p30, p15, p35, E199L and F317L produced using the recombinant vector of the present invention. The above antigen proteins are produced from separate recombinant vectors (i.e., from separate nucleic acid molecules), respectively, and may be produced from a recombinant vector (i.e., a single nucleic acid molecule) comprising polynucleotides encoding two or more recombinant proteins. In particular, the main object of the present invention is to provide lectin, CD2v, p54, p72 and p30 recombinant antigen proteins produced by using the recombinant vector of the present invention.

In one embodiment of the invention, the lectin, CD2v, p54, p72, p30, p15, p35, E199L and F317L recombinant antigen proteins may be water soluble. More specifically, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of lectin, CD2v, p54, p72, p30, p15, p35, E199L and F317L recombinant antigen proteins expressed in plant bodies are dissolved in water-soluble fractions.

In another specific example of the present invention, the lectin, CD2v, p54, p72, p30, p15, p35, E199L and F317L recombinant antigen proteins can be isolated and purified at a purity of 85% or more. More specifically, in lectin, CD2v, p54, p72, p30, p15, p35, E199L and F317L recombinant antigen proteins expressed in plant bodies using the recombinant vector of the present invention, lectin, CD2v, p54, p72, p30, p15, p35, E199L and F317L recombinant antigen proteins having a purity of 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% can be obtained when conventional isolation and purification methods are used.

According to another aspect of the present invention, there is provided a vaccine composition comprising as an active ingredient a combination of african swine fever virus antigen proteins, wherein the combination of ASFV antigen proteins is at least one selected from the group consisting of lectin, CD2v, p72, p54, p30, p15, p35, E199L and/or F317L proteins. Preferably, the ASFV antigen protein may be a combination of one or more selected from the group consisting of lectin, CD2v, p72, p54 and p 30. Most preferably, the above combinations of ASFV antigen proteins consist of lectin, CD2v, p72, p54 and p 30. The present invention also provides a pharmaceutical composition for preventing or treating african swine fever, comprising as an active ingredient a combination of african swine fever virus antigen proteins, wherein the combination of ASFV antigen proteins is one or more selected from the group consisting of lectin, CD2v, p72, p54, p30, p15, p35, E199L and/or F317L proteins. Preferably, the pharmaceutical composition is a pharmaceutical composition for preventing african swine fever.

The following description of the vaccine composition of the present invention applies equally to the pharmaceutical composition of the present invention, and conversely, the description of the pharmaceutical composition of the present invention applies equally to the vaccine composition of the present invention.

Preferably, in the case where the combination of ASFV antigen proteins described above includes lectin protein and CD2v protein, the combination of ASFV antigen proteins described above may be composed of three or more antigen proteins. That is, in addition to the lectin proteins described above and the CD2v proteins described above, the composition comprising lectin proteins and CD2v proteins may also comprise other ASFV antigen proteins (e.g., P72, P54, and/or P30).

Preferably, the above-mentioned ASFV antigen protein comprised in the vaccine composition of the present invention is characterized in that it is produced using the recombinant vector of the present invention. Preferably, the above ASFV antigen protein is characterized in that it is produced in a plant body using the recombinant vector of the present invention.

Furthermore, the vaccine composition of the present invention is characterized by not comprising ASFV antigen proteins other than lectin, CD2v, p72, p54 or p30 recombinant proteins. Preferably, ASFV antigen proteins other than the lectin, CD2v, p72, p54 or p30 recombinant proteins described above may be one or more selected from the group consisting of p15, p35, E199L and F317L. That is, in a most preferred embodiment, the vaccine composition of the present invention is a vaccine composition comprising five recombinant antigen proteins of lectin, CD2v, p54, p72 and p30, and is characterized in that the antibody production induction effect on ASFV antigen, ASFV infection inhibition effect, african swine fever prevention effect and the like are superior to those of a vaccine further comprising additional antigens (p 15, p35, E199L, F317L and the like). For example, the vaccine composition may induce antibody production against ASFV antigens as compared to a vaccine further comprising p15, p35, E199L, F317L, etc.

Furthermore, the present invention provides a method for preventing or treating african swine fever, comprising the step of administering the vaccine composition or the pharmaceutical composition of the present invention to an individual in need thereof. Preferably, the method for preventing or treating african swine fever of the present invention is characterized in that ASFV antigen proteins (e.g., p15, p35, E199L and/or F317L) other than lectin, CD2v, p72, p54 or p30 recombinant proteins are not administered to the above-mentioned individuals.

In one embodiment of the invention, the vaccine composition may further comprise an adjuvant (adjuvant). Preferably, the above adjuvant may be mineral oil (mineral oil) or an emulgen-based adjuvant, more preferably a Drakeol 5 oil adjuvant, most preferably SEA1, but is not limited thereto.

The term "Adjuvant" as used in this specification refers to a material or composition that is added to a vaccine or pharmaceutical active ingredient to increase or affect an immune response. Representatively, adjuvants generally refer to carriers (carriers) or auxiliary materials for immunogens (immunogens) and/or other pharmaceutically active materials or compositions. In general, the term "adjuvant" should be interpreted broadly to refer to a wide range of substances or strategies (stratagerm) capable of enhancing the immunogenicity of an antigen incorporated into or administered with an adjuvant. In addition, adjuvants may include, but are not limited to, classified as immunopotentiators (immune potentiator), antigen delivery systems, or combinations thereof. Examples of suitable adjuvants include aluminum hydroxide, freund's complete or incomplete adjuvant, DEAE-dextran, levamisole, PCG and polyI: C or polyA: U. In one embodiment of the invention, SEA1 adjuvants based on Drakeol 5 oil are used.

In the present specification, "vaccine" refers to a biological agent containing an antigen that causes an immune response in an organism, and refers to an immunogen that generates immunity in an organism by injection or oral administration to a human or animal to prevent an infectious disease. The animal is a human or non-human animal, and the non-human animal is a pig, a cow, a horse, a dog, a goat, a sheep, or the like, but is not limited thereto.

In the present specification, "solubility" refers to the degree to which a target protein or peptide can be dissolved in a solvent suitable for administration to a human body. Specifically, it may be the degree to which the solute is saturated with respect to the solvent at a particular temperature. The solubility can be determined by determining the saturation level of the solute, for example, after adding an excessive amount of the solute to the solvent, stirring it and filtering, the concentration can be determined using a UV spectrometer or HPLC, etc., but is not limited thereto, and the high solubility has the advantage of facilitating separation and purification of the recombinant protein and inhibiting aggregation of the recombinant protein to maintain the physiological or pharmacological activity of the recombinant protein.

The content of the above antigen protein in the vaccine composition or the pharmaceutical composition of the present invention may be appropriately adjusted according to symptoms of the disease, the degree of progress of the symptoms, the state of the patient, etc., and may be, for example, 0.0001 to 99.9 weight percent, or 0.001 to 50 weight percent based on the total composition weight, but is not limited thereto. The content ratio is a value based on the dry amount of the solvent to be removed.

The vaccine or pharmaceutical compositions of the invention may also include suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions. The excipient may be, for example, one or more selected from the group consisting of diluents, binders, disintegrants, lubricants, adsorbents, humectants, film coating materials and controlled release additives.

The vaccine composition or the pharmaceutical composition of the present invention, respectively, can be formulated according to a usual method into the following forms such as: powder, granule, sustained-release granule, enteric granule, liquid, eye drop, elixir, emulsion, suspension, spirit, lozenge, aromatic water, lemon water, tablet, sustained-release tablet, enteric tablet, sublingual tablet, hard capsule, soft capsule, sustained-release capsule, enteric capsule, pill, tincture, soft extract, dry extract, liquid extract, injection, capsule, perfusion, plaster, emulsion, paste, spray, inhalant, patch, sterile injection or aerosol. The external preparation may be formulated as cream, gel, patch, spray, ointment, plaster, emulsion, liniment, paste or cataplasm.

As carriers, excipients and diluents which may be included in the vaccine or pharmaceutical compositions of the invention, lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylparaben, propylhydroxybenzoate, talc, magnesium stearate and mineral oil may be used.

In the case of the formulation, it is prepared using a conventional diluent or excipient such as a filler, thickener, binder, wetting agent, disintegrant, and surfactant.

As additives for tablets, powders, granules, capsules, pills and lozenges of the present invention, there may be used, for example, corn starch, potato starch, wheat starch, lactose, white sugar, glucose, fructose, D-mannitol, precipitated calcium carbonate, synthetic aluminum silicate, calcium hydrogen phosphate, calcium sulfate, sodium chloride, sodium bicarbonate, purified lanolin, microcrystalline cellulose, dextrin, sodium alginate, methylcellulose, sodium carboxymethylcellulose, kaolin, urea, colloidal silica gel, hydroxypropyl starch, hydroxypropyl methylcellulose (HPMC) 1928, HPMC 2208, HPMC 2906, HPMC 2910, propylene glycol, casein, calcium lactate and Excipients such as gelatin, acacia, ethanol, agar powder, cellulose acetate phthalate, carboxymethyl celluloseBinders such as calcium cellulose, glucose, purified water, sodium caseinate, glycerol, stearic acid, sodium carboxymethyl cellulose, sodium methyl cellulose, microcrystalline cellulose, dextrin, hydroxy cellulose, hydroxypropyl starch, hydroxymethyl cellulose, purified shellac, starch, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, and polyvinylpyrrolidone; and disintegrants such as hydroxypropyl methylcellulose, corn starch, agar powder, methylcellulose, bentonite, hydroxypropyl starch, sodium carboxymethylcellulose, sodium alginate, calcium carboxymethylcellulose, calcium citrate, sodium lauryl sulfate, silicic anhydride, 1-hydroxypropyl cellulose, dextran, ion exchange resins, polyvinyl acetate, formaldehyde-treated casein and gelatin, alginic acid, amylose, guar gum, sodium bicarbonate, polyvinylpyrrolidone, calcium phosphate, gel starch, acacia, pullulan, pectin, sodium polyphosphate, ethylcellulose, white sugar, magnesium aluminum silicate, a sorbitol solution, light anhydrous silicic acid and the like; and lubricants such as calcium stearate, magnesium stearate, stearic acid, hydrogenated vegetable oil, talc, pine powder, kaolin, vaseline, sodium stearate, cocoa butter, sodium salicylate, magnesium salicylate, polyethylene glycol (PEG) 4000, PEG 6000, liquid paraffin, hydrogenated soybean oil (Lubri wax), aluminum stearate, zinc stearate, sodium lauryl sulfate, magnesium oxide, polyethylene glycol (Macrogol), synthetic aluminum silicate, silicic anhydride, higher fatty acid, higher alcohol, silicone oil, paraffin oil, polyethylene glycol fatty acid ether, starch, sodium chloride, sodium acetate, sodium oleate, dl-leucine, and light anhydrous silicic acid.

As the additive of the liquid agent of the present invention, water, dilute hydrochloric acid, dilute sulfuric acid, sodium citrate, sucrose monostearate, polyoxyethylene sorbitol fatty acid ester (diester), polyoxyethylene monoalkyl ether, lanolin ester, acetic acid, hydrochloric acid, aqueous ammonia, ammonium carbonate, potassium hydroxide, sodium hydroxide, prolamine, polyvinylpyrrolidone, ethylcellulose, sodium carboxymethyl cellulose and the like can be used.

In the syrup of the present invention, a white sugar solution, other sugar or sweetener, etc. may be used, and if necessary, a flavoring agent, coloring agent, preservative, stabilizer, suspending agent, emulsifying agent, viscosity-increasing agent, etc. may be used.

In the emulsion of the present invention, purified water may be used, and an emulsifier, a preservative, a stabilizer, a fragrance, and the like may be used as needed.

In the suspension of the present invention, suspending agents such as acacia, tragacanth, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, sodium alginate, hydroxypropylmethyl-cellulose, HPMC 1828, HPMC 2906, HPMC 2910 and the like can be used, and surfactants, preservatives, stabilizers, colorants and fragrances can be used as required.

The injection of the present invention may comprise: such as distilled water for injection, 0.9% sodium chloride injection, ringer's solution, glucose injection, glucose+sodium chloride injection, PEG, ringer's solution of lactic acid, ethanol, propylene glycol, non-volatile oil-sesame oil, cottonseed oil, peanut oil, soybean oil, corn oil, ethyl oleate, isopropyl myristate, benzene benzoate, and the like; cosolvents such as sodium benzoate, sodium salicylate, sodium acetate, urea, carbamate, monoethyl acetamide, phenylbutazone, propylene glycol, tween series, niacinamide, hexamine, and dimethylacetamide; buffers such as weak acids and salts thereof (acetic acid and sodium acetate), weak bases and salts thereof (ammonia and ammonium acetate), organic compounds, proteins, albumin, peptones and gums, and the like; isotonic agents such as sodium chloride; such as sodium bisulphite (NaHSO) ₃ ) Carbon dioxide gas, sodium metabisulfite (Na) ₂ S ₂ O ₅ ) Sodium sulfite (Na) ₂ SO ₃ ) Nitrogen (N) ₂ ) Stabilizers such as ethylenediamine tetraacetic acid; sulfating agents such as 0.1% sodium bisulfite, sodium formaldehyde sulfoxylate, thiourea, disodium edetate, sodium acetonide, and the like; analgesic agents such as benzyl alcohol, chlorobutanol, procaine hydrochloride, dextrose, and calcium gluconate; suspending agents such as CMC sodium, sodium alginate, tween 80, and aluminum monostearate.

In the suppositories of the present invention, substances such as cocoa butter, lanolin, witepsol, polyethylene glycol, glycerogelatin, methylcellulose, carboxymethylcellulose, mixtures of stearic acid and oleic acid, subnal, cottonseed oil, peanut oil, palm oil, cocoa butter+cholesterol, lecithin, lanete wax, glycerol monostearate, tween or Span, imhausen, monolan (propylene glycol monostearate), glycerin, adeps solids, butyrun Tego-G, cebes Pharma16, hexalide base 95, cotomar, hydrokey SP, S-70-XXA, S-70-XX75 (S-70-XX 95), hydrokey 25, hydrokey 711, idropstal, massa escript (Massa Estrarium A, AS, B, C, D, E, I, T), masa-MF, masupol, masupol-15, neospor-N, paramount-B, supposiro (supposo OSI, OSIX, A, B, C, D, H, L), matrix IV (95, 299), matrix IV (N, es), matrix Tg (9757), and the like can be used.

Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid formulations are prepared by mixing at least one excipient such as starch, calcium carbonate (calcium carbonate), sucrose (sucrose), lactose (lactose), gelatin and the like with the above extract. In addition to simple excipients, lubricants such as magnesium stearate and talc are used.

Examples of the liquid preparations for oral administration include suspensions, oral liquids, emulsions, syrups and the like, and these liquid preparations may include various types of excipients, for example, wetting agents, sweeteners, fragrances, antistaling agents and the like, in addition to simple usual diluents such as water and liquid paraffin. Formulations for parenteral administration include sterile aqueous solutions, nonaqueous solvents, suspensions, emulsions, lyophilized formulations and suppositories. Nonaqueous solvents and suspensions may use propylene glycol (propylene glycol), polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.

The vaccine or pharmaceutical compositions of the invention are administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio suitable for medical treatment, and the effective dosage level may be determined according to the type of disease in the patient, the severity of the disease, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration, the rate of excretion, the period of treatment, the drug being co-administered, and other factors well known in the medical arts.

The vaccine composition or the pharmaceutical composition of the present invention can be administered as a single therapeutic agent or in combination with other therapeutic agents, can be administered sequentially or simultaneously with the conventional therapeutic agents, and can be administered in a single dose or in multiple doses. With all of the above factors in mind, it is important to administer the composition in a minimum amount that can achieve maximum efficacy without any side effects, and this can be readily determined by one of ordinary skill in the art.

The vaccine or pharmaceutical compositions of the invention may be administered to an individual via a variety of routes. All methods of administration can be predicted, for example, by oral administration, subcutaneous injection, intraperitoneal administration, intravenous injection, intramuscular injection, perispinal space (intrathecal) injection, sublingual administration, administration via oral mucosa, intrarectal insertion, intravaginal insertion, intraocular administration, otic administration, intranasal administration, inhalation, spraying via the mouth or nose, transdermal administration, and the like. Preferably, the composition of the present invention is muscle administrable.

The vaccine composition or the pharmaceutical composition of the present invention is determined according to the type of the drug as an active ingredient, together with various relevant factors such as the disease to be treated, the administration route, the age, sex and weight of the patient, and the severity of the disease. Specifically, an effective amount of the composition of the present invention may vary depending on the age, sex, and weight of the patient, and is generally administered at 0.001 to 150mg per 1kg of body weight, preferably at 0.01 to 100mg per 1kg of body weight, and may be administered daily or every other day, or 1 to 3 times per 1 day. However, the amount may be increased or decreased depending on the administration route, severity of the disease, sex, weight, age, etc., and thus the above dose is not intended to limit the scope of the present invention in any way.

In the present invention, "individual" refers to a subject in need of treatment for a disease, more specifically, to mammals such as humans or non-human primates, mice, rats, dogs, cats, horses, and cows. For example, in the present specification, "individual (individual)" means a subject capable of administering the recombinant african swine fever antigen protein of the present invention, which subject is not limited.

In the present invention, "administering" means providing the composition of the present invention to an individual by using any suitable method.

In the present invention, "preventing" means all effects of inhibiting or delaying the onset of a target disease, "treating" means all effects of alleviating or beneficially altering the target disease and the abnormal metabolic symptoms caused thereby via administration of the pharmaceutical composition of the present invention, and "ameliorating" means all effects of reducing parameters (e.g., the degree of symptoms) associated with the target disease via administration of the composition of the present invention. For example, in the present specification, "prevention" means all effects of inhibiting african swine fever or delaying the onset of african swine fever by administering the recombinant african swine fever antigen protein of the present invention. Furthermore, in the present specification, "treatment" means all effects of alleviating or beneficially altering symptoms of african swine fever by administering the recombinant african swine fever antigen protein of the present invention.

Further illustratively, the vaccine compositions of the present invention may be formulated for use in oral formulations (e.g., powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols) as well as sterile injectable solutions, according to conventional methods. In the case of the formulation, it can be prepared using a diluent or excipient such as a filler, thickener, binder, wetting agent, disintegrant, surfactant, etc., which are commonly used. The solid preparation for oral administration may be a tablet, a pill, a powder, a granule, a capsule, or the like, and such a solid preparation may be prepared by mixing one or more excipients such as starch, calcium carbonate (calcium carbonate), sucrose (sucrose), lactose (lactose), or gelatin with a pseudo-lecithin emulsifier. Besides simple excipients, lubricants such as magnesium stearate and talc may be used. As the liquid preparation for oral administration, suspension, oral liquid, emulsion, syrup, or the like can be used, and various types of excipients such as wetting agents, sweeteners, fragrances, and antistaling agents can be contained in addition to water, liquid paraffin, which are commonly used as simple diluents. Formulations for parenteral administration may be in the form of sterile aqueous solutions, nonaqueous solvents, suspensions, emulsions, lyophilisates. As the nonaqueous solvent or suspension, vegetable oils such as propylene glycol (propylene glycol), polyethylene glycol, olive oil, or injectable esters such as ethyl oleate may be used.

Routes of administration of the vaccine compositions of the present invention may include, but are not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal administration. Oral or parenteral administration is preferred. The term "parenteral" as used in this application means subcutaneous, intradermal, intravenous, intramuscular, intra-articular, intracapsular, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques. The vaccine compositions of the present invention can also be used for rectal administration in the form of suppositories.

The dosage of the vaccine composition or the pharmaceutical composition of the present invention is selected in consideration of the age, weight, sex, physical condition, etc. of the individual. The amount required to induce an immunoprotection response in an individual without any side effects may vary depending on the recombinant protein used as the immunogen and any presence of excipients.

Preferably, the content of lectin, CD2v, p54, p72, p15, p35, E199L and/or F317L may be 10 μg to 1mg, 10 μg to 900 μg, 10 μg to 800 μg, 10 μg to 700 μg, 10 μg to 600 μg, 10 μg to 500 μg, 10 μg to 400 μg, 10 μg to 300 μg, 10 μg to 200 μg, 50 μg to 150 μg, 70 μg to 130 μg, 80 μg to 120 μg or 90 μg to 110 μg, respectively, the content of p30 may be 1 μg to 100 μg, 1 μg to 90 μg, 1 μg to 80 μg, 1 μg to 70 μg, 1 μg to 60 μg, 1 μg to 50 μg, 10 μg to 50 μg, 15 μg to 45 μg, 20 μg to 40 μg or 25 μg, but is not limited thereto.

According to another aspect of the present invention there is provided a vaccine kit for preventing african swine fever comprising the vaccine composition of the present invention. In addition to the vaccine composition of the present invention, the above-described kit may include, without limitation, tools, reagents, etc. generally used in the art for vaccine administration. The kit may include instructions describing characteristics or information about the vaccine composition, recombinant vector, and the like of the present invention, and may include instructions on the method for producing the vaccine composition of the present invention.

According to another aspect of the present invention, there is provided a method for preparing a recombinant ASFV antigen protein comprising the steps of:

According to another aspect of the present invention, there is provided a method of manufacturing a vaccine composition or vaccine kit for preventing african swine fever, comprising the steps of:

step (S1), transforming the recombinant vector of the present invention into a plant;

step (S2) of separating and purifying the recombinant antigen protein from the plant body or the culture solution; and

And (S3) preparing a vaccine composition or a vaccine kit by using the separated and purified recombinant antigen protein.

The specific explanation about the "transformation" of the above step (S1) is as described above. The transformation method of the above step (S1) is not limited to a specific kind, but preferably, may be performed by an Agrobacterium-mediated transformation method. Specifically, the step (S1) may include: a step of transforming the recombinant vector of the present invention into an Agrobacterium strain; a step of culturing the transformed Agrobacterium strain; and a step of applying (injecting or inoculating) the above-mentioned cultured strain to a plant body. Preferably, the plant body may be tobacco.

The above step (S2) of separating and purifying the recombinant antigen protein may be carried out without limitation by using protein separation and purification methods well known in the art. Preferably, the above-mentioned separation of proteins can be performed by adding a protein extraction solution to the transformed plant body. Furthermore, purification of the above-mentioned proteins can be achieved by performing chromatography. Preferably, the chromatography may be affinity chromatography, and the ligand used in this case may be protein A, ni-IDA, etc., but is not limited thereto.

According to another aspect of the present invention, there is provided a feed composition for preventing african swine fever, comprising a combination of african swine fever virus antigen proteins as an active ingredient, wherein the combination of ASFV antigen proteins comprises at least one combination selected from the group consisting of lectin, CD2v, p72, p54 and p30 proteins. Preferably, in the case where the combination of ASFV antigen proteins comprises lectin protein and CD2v protein, the combination of ASFV antigen proteins is composed of three or more antigen proteins.

Preferably, the above-described ASFV antigen protein comprised in the feed composition of the present invention is produced using the recombinant vector of the present invention. Preferably, the above ASFV antigen protein is characterized in that it is produced in a plant body using the recombinant vector of the present invention.

Furthermore, preferably, the feed composition of the present invention contains lectin, CD2v, p54, p72 and p30 recombinant antigen proteins as an active ingredient, and most preferably, the above feed composition does not contain ASFV antigen proteins (p 15, p35, E199L and F317L) other than lectin, CD2v, p72, p54 or p30 recombinant proteins.

In the above-mentioned feed composition, specific examples of the "feed" include by-products of pork, beef, chicken, etc., corn, rice, ordinary straw, weeds, pasture, green manure, hay, mountain weeds, etc., but are not limited thereto, and can be used for raising livestock without limitation. The method of adding the lectin, CD2v, p54, p72 and p30 recombinant antigen proteins of the present invention to the feed is not limited to this, and there may be mentioned mechanical mixing, adsorption and absorption methods.

Hereinafter, in order to assist understanding of the present invention, preferred embodiments will be presented. However, the following examples are provided only for easier understanding of the present invention, and the contents of the present invention are not limited to the following examples.

Examples (example)

Example 1 preparation of recombinant vectors expressing antigens of African swine fever Virus

As shown in the restriction map of FIG. 1, a plant expression vector was prepared which was recombined in such a manner that the African swine fever virus antigen protein lectin, CD2v, p72, p54, p30, p15, p35, E199L or F317L was expressed in the plant body. In more detail, gene information on lectin, CD2v, p72, p54, p30, p15, p35, E199L and F317L proteins of African swine fever virus was ensured, and lectin protein-encoding gene (SEQ ID NO: 2), CD2v protein-encoding gene (SEQ ID NO: 4), p72 protein-encoding gene (SEQ ID NO: 6), p54 protein-encoding gene (SEQ ID NO: 8), p30 protein-encoding gene (SEQ ID NO: 10), p15 protein-encoding gene (SEQ ID NO: 12), p35 protein-encoding gene (SEQ ID NO: 14), E199L protein-encoding gene (SEQ ID NO: 16) and F317L protein-encoding gene (SEQ ID NO: 18) were synthesized, respectively, by expression-optimized sequences in plants.

The specific composition of each recombinant vector is as follows.

Recombinant vectors for expression of lectin antigen proteins

A CaMV 35S promoter (promoter) gene and an HSP terminator (terminator) were inserted into the pCAMBIA1300 vector, and a polynucleotide encoding an NB signal peptide (signal peptide) (SEQ ID NO: 20), a polynucleotide encoding a polyhistidine-tag (polyhistidine tag) (SEQ ID NO: 26), a polynucleotide encoding a lectin antigen recombinant protein of African swine fever virus (SEQ ID NO: 2), a polynucleotide encoding a pFC2 (gardine Fc) fragment (SEQ ID NO: 28) and a polynucleotide encoding an HDEL (His-Asp-Glu-Leu) peptide (SEQ ID NO: 30) were sequentially connected therebetween, thereby preparing a plant expression vector of a lectin antigen protein of African swine fever virus.

Recombinant vector for expressing CD2v antigen protein

A CaMV 35S promoter gene and an HSP terminator were inserted into the pCAMBIA1300 vector, and a polynucleotide encoding an NB signal peptide (SEQ ID NO: 20), a polynucleotide encoding an M domain (SEQ ID NO: 24), a polynucleotide encoding a CD2v antigen recombinant protein of African swine fever virus (SEQ ID NO: 4), a polynucleotide encoding a pFC2 fragment (SEQ ID NO: 28) and a polynucleotide encoding an HDEL peptide (SEQ ID NO: 30) were sequentially connected therebetween, thereby preparing a plant expression vector for a CD2v antigen protein of African swine fever virus.

Recombinant vector for expressing p72 antigen protein

The hygromycin resistance gene as a screening marker of the pCAMBIA1300 vector was replaced with the human calreticulin (human calreticulin) 1 gene, and the MacT promoter gene with T-substituted 3' -terminal nucleotide and the Arabidopsis RD29B terminator were inserted, and the polynucleotide encoding the BiP signal peptide (SEQ ID NO: 22), the polynucleotide encoding the p72 antigen recombinant protein of African swine fever virus (SEQ ID NO: 6), the polynucleotide encoding the pFC2 fragment (SEQ ID NO: 28) and the polynucleotide encoding the HDEL peptide (SEQ ID NO: 30) were sequentially connected therebetween, thereby preparing a plant expression vector for the p72 antigen protein of African swine fever virus.

Recombinant vector for expressing p54 antigen protein

A CaMV 35S promoter gene and an HSP terminator were inserted into the pCAMBIA1300 vector, and a polynucleotide encoding an NB signal peptide (SEQ ID NO: 20), a polynucleotide encoding a p54 antigen recombinant protein of African swine fever virus (SEQ ID NO: 8), a polynucleotide encoding a pFC2 fragment (SEQ ID NO: 28) and a polynucleotide encoding an HDEL peptide (SEQ ID NO: 30) were sequentially connected therebetween, thereby preparing a plant expression vector of a p54 antigen protein of African swine fever virus.

Recombinant vector for expressing p30 antigen protein

A CaMV 35S promoter gene and an HSP terminator were inserted into the pCAMBIA1300 vector, and a polynucleotide encoding an NB signal peptide (SEQ ID NO: 20), a polynucleotide encoding a p30 antigen recombinant protein of African swine fever virus (SEQ ID NO: 10), a polynucleotide encoding a polyhistidine-tag (SEQ ID NO: 26) and a polynucleotide encoding an HDEL peptide (SEQ ID NO: 30) were sequentially connected therebetween, thereby preparing a plant expression vector for the p30 antigen protein of African swine fever virus.

Recombinant vector for expressing p15 antigen protein

A CaMV 35S promoter gene and an HSP terminator were inserted into the pCAMBIA1300 vector, and a polynucleotide encoding an NB signal peptide (SEQ ID NO: 20), a polynucleotide encoding a p15 antigen recombinant protein of African swine fever virus (SEQ ID NO: 12), a polynucleotide encoding a pFC2 fragment (SEQ ID NO: 28) and a polynucleotide encoding an HDEL peptide (SEQ ID NO: 30) were sequentially connected therebetween, thereby preparing a plant expression vector for a p15 antigen protein of African swine fever virus.

Recombinant vector for expressing P35 antigen protein

A CaMV 35S promoter gene and an HSP terminator were inserted into the pCAMBIA1300 vector, and a polynucleotide encoding an NB signal peptide (SEQ ID NO: 20), a polynucleotide encoding a p35 antigen recombinant protein of African swine fever virus (SEQ ID NO: 14), a polynucleotide encoding a pFC2 fragment (SEQ ID NO: 28) and a polynucleotide encoding an HDEL peptide (SEQ ID NO: 30) were sequentially connected therebetween, thereby preparing a plant expression vector of a p35 antigen protein of African swine fever virus.

Recombinant vector for expressing E199L antigen protein

The hygromycin resistance gene as a screening marker of the pCAMBIA1300 vector was replaced with the radish wrinkling virus coat protein (turnip crinkle virus-coat protein, TCV-CP) gene, and a MacT promoter gene with T-substituted MacT terminal nucleotide and Arabidopsis RD29B terminator were inserted, and a polynucleotide encoding NB signal peptide (SEQ ID NO: 20), a polynucleotide encoding E199L antigen recombinant protein of African swine fever virus (SEQ ID NO: 16), a polynucleotide encoding pFC2 fragment (SEQ ID NO: 28) and a polynucleotide encoding HDEL peptide (SEQ ID NO: 30) were sequentially connected therebetween, thereby preparing a plant expression vector of E199L antigen protein of African swine fever virus.

Recombinant vector for expressing F317L antigen protein

The hygromycin resistance gene as a screening marker of the pCAMBIA1300 vector was replaced with the radish wrinkling virus coat protein gene, and the MacT promoter gene with T-substituted 3' -terminal nucleotide and the Arabidopsis RD29B terminator were inserted, and the polynucleotide encoding NB signal peptide (SEQ ID NO: 20), the polynucleotide encoding F317L antigen recombinant protein of African swine fever virus (SEQ ID NO: 18), the polynucleotide encoding pFC2 fragment (SEQ ID NO: 28) and the polynucleotide encoding HDEL peptide (SEQ ID NO: 30) were sequentially connected therebetween, thereby preparing a plant expression vector of F317L antigen protein of African swine fever virus.

EXAMPLE 2 confirmation of expression of recombinant ASF Virus antigen protein

2-1 transient expression of plant expression vectors (transient expression)

The plant expression recombinant vectors of the african swine fever antigen proteins (lectin, CD2v, p72, p54, p30, p15, p35, E199L and F317L) prepared in example 1 above were transformed into agrobacterium LBA4404 strain, respectively, using an electric shock method (electrophoresis). For transformed Agrobacterium, 1mL of the primary culture broth was inoculated into 50mL of the new YEP medium after shaking culture for 16 hours at 28℃in 5mL of YEP liquid medium (yeast extract 10g, peptone 10g, naCl 5g, kanamycin 50mg/L, rifampicin 25 mg/L), and shaking culture was performed for 6 hours at 28 ℃. The Agrobacterium cultured by the above method was centrifuged (7000 rpm,4 ℃ C., 5 minutes) and collected, and then suspended in an Infiltration (Infiltration) buffer [10mM MES (pH 5.7), 10mM MgCl ₂ 20 mu M acetosyringone]So that the absorbance (O.D) value was 1.0 at a wavelength of 600 nm. The agroinfiltration (Agro-infusion) method was performed by infusion of an Agro suspension to the back of the leaves (Nicotiana benthamiana) of banshi tobacco using a syringe with a needle removed.

Separation and purification of antigenic proteins of ASF virus

In order to isolate and purify the recombinant proteins from the Banbury's tobacco leaves prepared in the above example 2-1, a protein extraction solution was added to Ban Shi tobacco leaves expressing each recombinant protein, and after the tissue was broken by a stirrer, the protein extraction solution was recovered by centrifugation at 13000rpm at 4℃for 30 minutes. In order to separate and purify each ASF virus antigen protein from the above extract, affinity chromatography is performed on a column packed with protein a-sepharose resin. The column was packed with protein a resin and then equilibrated with a washing solution. After the recovered protein extract was applied to the column and equilibrated, the resin was washed by flowing a washing solution, and each recombinant protein was eluted by an eluting solution. After adding a neutralizing solution to the elution solution containing the recombinant antigen protein to neutralize to an appropriate pH, buffer exchange and concentration were performed using a 30kDa cut-off filter. The concentration of the isolated and purified recombinant antigen protein was confirmed by coomassie staining (Coomassie staining) after electrophoresis (SDS-PAGE).

The p30 protein was isolated and purified by the following procedure. Protein extract was recovered by adding a protein extract solution to Ban Shi tobacco leaves expressing p30, disrupting the tissues with a stirrer, and centrifuging at 13000rpm and 4℃for 30 minutes. In order to separate and purify p30 from the above extract, affinity chromatography was performed on a column packed with Ni-IDA resin. First, the column was filled with Ni-IDA resin, and then equilibrated with a washing liquid. After the recovered protein extract was applied to the column and equilibrated, the resin was washed by flowing a washing solution, and p30 protein was eluted by an eluting solution. For the elution solution containing p30 protein, buffer exchange and concentration were performed using a 10kDa cut-off filter. The concentration of the isolated and purified p30 protein was confirmed by coomassie staining after electrophoresis (SDS-PAGE).

As a result, it was confirmed that the African swine fever virus antigen protein of the present invention was purified well without any mutation or deformation as compared with the original protein, as shown in FIGS. 2 to 10 b. These results confirm that in the case of expressing a protein in a plant, the problem of reduced production efficiency due to the variation in sugar structure was not found, and that the african swine fever virus recombinant antigen protein of the present invention was well produced in a plant.

The conditions for isolation and purification of each recombinant antigen protein and the results are as follows.

Lectin antigen protein (molecular weight 40651.82; FIG. 2)

(1) Protein extraction conditions: ban Shi tobacco leaf 1kg, protein extract 2L

(2) Protein separation and purification: after 30 minutes of binding in a column filled with about 80mL of protein A resin, resin down for 20 minutes

-extract (extraction buffer)/wash: 50mM Tris-Cl (pH 7.2), 100mM NaCl,100mM Sodium sulfite (Sodium sulfate) (-W), 0.5% Triton X-100 (-W2), 1.5% PVPP (-W)

Eluent (elution buffer): 50mM Sodium citrate (pH 3.0), 100mM NaCl

-a neutralisation buffer: 1M Tris (neutralization pH 7.5)

-final buffer: 50mM sodium citrate, about 150mM Tris-Cl,100mM NaCl,pH 7.5

(3) Final protein concentration (based on Nanodrop (spectrophotometer): 1.02 μg/μl

(4) Final yield (based on Nanodrop): 54mg/kg

CD2v antigen protein (molecular weight 55214.70; FIG. 3)

(1) Protein extraction conditions: ban Shi tobacco leaf 1kg, protein extract 2L

(2) Protein separation and purification: after 60 minutes of adhesion in a column filled with about 100mL of protein A resin, resin down for 20 minutes

-extract/wash: 100mM Tris-Cl (pH 7.5), 154mM NaCl,0.5% Triton X-100 (-W2), 100mM sodium sulfite (-W), 1.5% PVPP (-W)

-eluent: 50mM sodium citrate (pH 3.0), 154mM NaCl

-a neutralisation buffer: 1M Tris (neutralization pH 7.5)

-final buffer: 50mM sodium citrate, 154mM NaCl, 1M Tris-HCl was added until pH7.5 was reached.

(3) Final protein concentration (Nanodrop basis): 1.2. Mu.g/. Mu.L

(4) Final yield (based on Nanodrop): 68.67mg/kg

The p72 antigen protein (molecular weight: 100405.77 (however, by 7 glycosylation sites (glycosylation) site) increased by 14 kDa); FIG. 4a and FIG. 4b

(1) Protein extraction conditions: ban Shi tobacco leaf 1kg, protein extract 2L

-eluent: 50mM sodium citrate (pH 3.0), 154mM NaCl

-a neutralisation buffer: 1.5M Tris (neutralization to pH 7.5)

(3) Final protein concentration (Nanodrop basis): 0.57. Mu.g/. Mu.L

(4) Final yield (based on Nanodrop): 7.06mg/kg

P54 antigen protein (molecular weight: 43956.09 (however, 2kDa increase through 1 glycosylation site); FIGS. 5a and 5 b) 5b)

(1) Protein extraction conditions: ban Shi tobacco leaf 0.1kg, protein extract 0.2L

(2) Protein separation and purification: after 70 minutes of adhesion in a column filled with about 10mL of protein A resin, resin down for 20 minutes

-an extract: 100mM Tris-Cl (pH 7.4), 154mM NaCl,0.5% Triton X-100 (-W2), 100mM sodium sulfite, 1.5% PVPP,0.5 XPI

-a washing liquid: 100mM Tris-Cl (pH 7.4), 154mM NaCl,0.5% Triton X-100 (-W2)

-eluent: 50mM sodium citrate (pH 3.0), 154mM NaCl

-final buffer: 1N NaOH (1M Tris-HCl was added until pH 7.4)

(3) Final protein concentration (Nanodrop basis): 1mg/ml

(4) Final yield (based on Nanodrop): 71mg/kg

P30 antigen protein (molecular weight: 22993.95; FIG. 6)

(1) Protein extraction conditions: ban Shi tobacco leaf 1kg, protein extract 2L

-an extract: 50mM Tris-Cl (pH 8.0), 300mM NaCl,10mM Imidazole, 0.5% Triton X-100, 50mM Glycine, 100mM Na ₂ SO ₃ 10mM Ascorbic Acid (Ascorbic Acid), 1.5% PVPP

-a washing liquid: 50mM Tris-Cl (pH 7.4), 300mM NaCl,10mM imidazole (W1, 2), 100mM imidazole (W3), 0.5% Triton X-100 (W1)

-eluent: 50mM Tris-Cl (pH 7.4), 300mM NaCl,250mM imidazole

-final buffer: 50mM Tris-Cl pH 7.4, 300mM NaCl,50mM KCl

(3) Final protein concentration (Nanodrop basis): 0.3. Mu.g/. Mu.L (volume: 93 ml)

(4) Final yield (based on Nanodrop): 27.9mg/kg

P15 antigen protein (molecular weight: 44114.34; FIG. 7a, FIG. 7 b)

(1) Protein extraction conditions: ban Shi tobacco leaf 1.5kg, protein extract 1L

-extract/wash: 50mM Tris-Cl (pH 7.2), 100mM NaCl,0.5% Triton X-100 (-W2), 100mM sodium sulfite (-W), 1.5% PVPP (-W), 1mM PMSF

-eluent: 50mM sodium citrate (pH 3.0), 100mM NaCl

-a neutralisation buffer: 0.5M NaOH (neutralization to pH 7.5)

-final buffer: 50mM sodium citrate, 100mM NaCl, 1M Tris-HCl was added until pH7.5 was reached.

(3) Final protein concentration (Nanodrop basis): 0.5mg/ml

(4) Final yield (based on Nanodrop): 98.6mg/kg

p35 antigen protein (molecular weight 61323.4)2; FIG. 8)

(1) Protein extraction conditions: ban Shi tobacco leaf 0.5kg, protein extract 1L

-extract/wash: 5mM Tris-Cl (pH 7.2), 100mM NaCl,0.5% Triton X-100 (-W2), 100mM sodium sulfite (-W), 15g PVPP (-W)

-eluent: 50mM sodium citrate (pH 3.0), 100mM NaCl

-a neutralisation buffer: 1M Tris (neutralization pH 7.5)

( 3) Final protein concentration (Nanodrop basis) 0.53 μg/μl (volume: about 110ml )

(4) Final yield (based on Nanodrop): 116.6mg/kg

E199L antigen protein (molecular weight: 46485.20 (however, 4kDa increase through 2 glycosylation sites); FIGS. 9a and FIG. 9 b)

(1) Protein extraction conditions: ban Shi tobacco leaf 1kg, protein extract 2L

-an extract: 100mM Tris-Cl (pH 7.2), 154mM NaCl,0.5% Triton X-100, 100mM sodium sulfite, 1.5% PVPP,1mM PMSF (DMSO)

-a washing liquid: 100mM Tris-Cl (pH 7.2), 154mM NaCl,0.5% Triton X-100 (-W2)

-eluent: 50mM sodium citrate (pH 3.0), 154mM NaCl

-a neutralisation buffer: 0.2N NaOH (neutralization to pH 7.5)

(3) Final protein concentration (Nanodrop basis): 1mg/ml

(4) Final yield (based on Nanodrop): 70.3mg/kg

F317L antigen eggWhite (molecular weight: 62777.73 (however, 6kDa increase through 3 glycosylation sites); FIG. 10a and FIG. 10b

(1) Protein extraction conditions: ban Shi tobacco leaf 100g and protein extract 200mL; or 1kg of Banyan tobacco leaves and 2L of protein extract

(2) Protein separation and purification: after 60 minutes of adhesion in a column filled with about 10mL of protein A resin, resin down for 20 minutes

-an extract: 100mM Tris-Cl (pH 7.5), 154mM NaCl,0.5% Triton X-100, 100mM sodium sulfite, 1.5% PVPP,1mM PMSF (DMSO)

-a washing liquid: 100mM Tris-Cl (pH 7.5), 154mM NaCl,0.5% Triton X-100 (-W2)

-eluent: 50mM sodium citrate (pH 3.0), 154mM NaCl

-a neutralisation buffer: 0.2N NaOH (neutralization to pH 7.5)

(3) Final protein concentration (Nanodrop basis): 1mg/ml

(4) Final yield (based on Nanodrop): 14mg/kg

EXAMPLE 3 confirmation of ASF Virus defenses of 5 antigens or 9 antigen vaccines

In order to confirm the effect of preventing ASF virus infection by administering the ASF virus antigen protein isolated and purified in the above example 2 and the stability of the above vaccine, a total of 18 pigs were divided into 3 groups of 6 as described in table 1 below, and a defensive ability test was performed. Specifically, the animal models were divided into 5 antigen vaccine (lectin, CD2v, p54, p72 and p30 combination) treatment group (G1), 9 antigen vaccine (lectin, CD2v, p54, p72, p30, p15, p35, E199L and F317L combination) treatment group (G2) and PBS treatment control group (G3). 100. Mu.g of ASFV antigen protein other than p30 was included in the vaccine, and 30. Mu.g of p30 was included, and 2mL of vaccine was administered to one pig at a time.

TABLE 1

The defensive power test schedule is shown in table 2. Vaccine was prepared by mixing recombinant protein antigen cocktail with SEA1 adjuvant (adjuvant), 2 intramuscular injections were made every 3 weeks, and after 2 weeks following the 2 injections, african swine fever virus (wild type ASF virus) challenge was inoculated into 2 of each group by intramuscular injection. The remaining 4 of each group were bred in the same breeding room together with pigs vaccinated with african swine fever virus and contacted with virus released from challenged pigs to induce horizontal infection (horizonal infection) (Sentinel). After challenge inoculation, symptoms were observed daily, and for pigs exhibiting symptoms of infection (high temperatures above 41.1 ℃) early euthanasia was performed before the end of the trial and serum was collected. Specifically, 3mL to 5mL of serum (18G to 20G, using 1 1/2 needle) was obtained from the jugular vein (jugular vein) or the anterior vena cava (anterior vena cava), and infected tissues such as lung, liver, spleen, kidney, lymph node, pancreas, etc. were isolated.

TABLE 2

The results of body temperature changes and survival of pigs after challenge inoculation are shown in figure 11. 2 of the groups vaccinated with african swine fever virus directly died one week before and after challenge. However, non-vaccinated pigs of group (G1) administered 5 antigen vaccines all exhibited body temperatures below 40.5 ℃ and all survived for 2 weeks. In contrast, none of the non-challenged vaccinated pigs 3 of group (G2) administered 9 antigen vaccines all died due to hyperthermia on day 11, one of the non-challenged vaccinated pigs 3 of control group (G3) was asymptomatic and survived, one died due to hyperthermia on day 13, and the remaining one exhibited hyperthermia from day 11 onwards, but survived during the 2 week experimental period.

The results described above show that the 5 antigen vaccines (lectin, CD2v, p54, p72 and p30 combinations) of the present invention have excellent swine fever virus prevention effect, and in particular, it is taught that the additional combinations of p15, p35, E199L and F317L antigen proteins (i.e., 9 antigen vaccines) that have been conventionally used as ASF virus vaccine antigens rather inhibit the function of the vaccine and reduce the african swine fever prevention effect.

Example 4 confirmation of viral (Viremia) levels in blood following challenge vaccination after administration of 5 antigen vaccines or 9 antigen vaccines

Next, the level of virus (Viremia; also referred to as "Viremia") in the blood of the pigs subjected to the challenge inoculation test of example 3 was measured, thereby confirming the african swine fever virus preventing effect of the vaccine of the present invention.

Specifically, in order to determine the level of virus in blood, serum was extracted from each pig on days 0, 3, 7, 10 and 14 after challenge inoculation, and after performing real-time polymerase chain reaction (real time-polymerase chain reaction) using ASF virus-specific primers and probes, ct values of each sample were compared. The ASF virus specific primer sequences used in the experiments are as follows.

TABLE 3 Table 3

As a result, as shown in fig. 12, in the pig (G1) administered with 5 antigen vaccines, ASF virus levels in blood were very low by 7 days after inoculation, no ASF virus (UD) was detected, virus was detected in part of pigs by 10 days after inoculation, but at very low levels, and no ASF virus was detected on day 14. In contrast, it was confirmed that in pigs (G2) administered with 9 antigen vaccines, ASF virus was detected from pigs exposed to-vaccinated ASF virus at day 7 after vaccination, the virus level in blood was increased at day 10 after vaccination, the virus level in the blood was further increased compared to the control group at the same time, and the virus preventing effect was rather decreased compared to no vaccine administration at all. Furthermore, as described above, for pigs administered 9 antigen vaccines, the symptoms of the febrile disease worsened on day 11 after challenge vaccination, thus euthanizing in advance.

The above results demonstrate that the 5 antigen vaccines (lectin, CD2v, p54, p72 and p30 combinations) of the present invention inhibit the infection and proliferation of ASF virus, thereby achieving excellent swine fever prevention effect. In particular, the additional combination of p15, p35, E199L and F317L antigen proteins (i.e., 9 antigen vaccines) that have been conventionally used as ASF virus vaccine antigens rather suppressed the vaccine effect, thus demonstrating that viral infection and in vivo proliferation could not be prevented at all.

Example 5 confirmation of the level of anti-ASFV antibodies after 5 antigens or 9 antigen vaccines were administered

Next, in order to confirm the level of anti-ASFV antibodies in serum, after vaccination using a panel coated with vaccine antigen, the extent of anti-p 30 antibody production was monitored over time in all individuals (carried out on days 0, 7, 14, 21, 28 and 35 after vaccination). In the case of the group to which 5 antigen vaccines were administered, the level of anti-p 30 antibody was detected at the 21 st day after vaccination, high levels of anti-p 30 antibody were detected in all individuals to which the vaccine was administered at the 28 th and 35 th days after vaccination, and a high average antibody response was confirmed compared to the group to which 9 antigen vaccines were administered (fig. 22).

The above results show that both the 5 and 9 antigen vaccines of the present invention can induce antibody production against swine fever virus antigen, and in particular, the 5 antigen vaccines can induce higher level of antibody production more rapidly than the 9 antigen vaccines.

As described above, the present inventors produced a vector for expression of african swine fever virus-specific proteins expressed in plant bodies, and confirmed that when an ASF virus vaccine combining the above recombinant proteins was administered to pigs, generation of antibodies of ASF virus could be stably induced without side effects. In particular, it was confirmed that in pigs administered 5 vaccines combined with 5 antigens (lectin, CD2v, p54, p72 and p 30), the body weight steadily increased even after exposure to the virus, ASFV viremia (viremia) or fever was not observed, and 100% survival was shown, and the 5 antigen vaccines effectively inhibited infection and in vivo proliferation of ASF virus, thereby inhibiting african swine fever. In particular, it was confirmed that the antibody production induction effect of the above 5 antigen vaccines was more excellent than that of 9 antigen vaccines (lectin, CD2v, p54, p72, p30, p15, p35, E199L and F317L), which means that the combination of the antigen proteins lectin, CD2v, p54, p72 and p30 can achieve more excellent african swine fever prevention effect than the conventional vaccine. Therefore, the 5 antigen vaccines of the present invention are expected to be used in a variety of new african swine fever virus vaccine compositions.

The foregoing description of the present invention has been presented for illustration, and it should be understood by those skilled in the art that the embodiments disclosed in the present specification may be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. The above-described embodiments are, therefore, illustrative in all respects, rather than restrictive.

Industrial applicability

Claims

1. A vaccine composition for preventing African swine fever comprising a combination of African swine fever virus antigen proteins as an active ingredient, characterized in that,

The combination of the African swine fever virus antigen proteins is a combination of more than one selected from the group consisting of lectin, CD2v, p72, p54 and p30 proteins,

however, when the combination of the african swine fever virus antigen proteins includes the lectin protein and the CD2v protein, the combination of the african swine fever virus antigen proteins is composed of three or more antigen proteins.

2. The vaccine composition of claim 1, wherein the vaccine composition,

the vaccine composition satisfies one or more characteristics selected from the group consisting of:

(a) The lectin protein comprises the amino acid sequence of SEQ ID NO. 1;

(b) The CD2v protein contains the amino acid sequence of SEQ ID NO. 3;

(c) The p72 protein comprises the amino acid sequence of SEQ ID NO. 5;

(d) The p54 protein comprises the amino acid sequence of SEQ ID NO. 7; and

(e) The p30 protein contains the amino acid sequence of SEQ ID NO. 9.

3. The vaccine composition of claim 1, wherein the vaccine composition,

the african swine fever virus antigen protein is produced using a recombinant vector comprising one or more african swine fever virus protein-encoding polynucleotides selected from the group consisting of:

4. The vaccine composition of claim 3, wherein the vaccine composition,

the recombinant vector further comprises one or more than one of the group consisting of:

(a) A polynucleotide encoding NB of SEQ ID NO. 19 or BiP of SEQ ID NO. 21;

(b) A polynucleotide encoding a pFC2 fragment of SEQ ID NO. 27;

(c) A polynucleotide encoding an HDEL peptide of SEQ ID No. 29; and

(d) A polynucleotide encoding the M domain of SEQ ID NO. 23 or the polyhistidine tag of SEQ ID NO. 25.

5. The vaccine composition of claim 3, wherein the vaccine composition,

the African swine fever virus antigen protein is produced in a plant body transformed with the recombinant vector.

6. The vaccine composition of claim 1, wherein the vaccine composition,

the vaccine composition further comprises an adjuvant.

7. The vaccine composition of claim 6, wherein the vaccine composition,

the above-mentioned adjuvant is mineral oil or Emuligen-based adjuvant.

8. A vaccine kit for preventing African swine fever is characterized in that,

a vaccine composition comprising any one of claims 1 to 7.

9. A method for preventing African swine fever is characterized in that,

comprising the step of administering the vaccine composition of claim 1 to an animal other than a human.

10. A feed composition for preventing African swine fever comprising a combination of African swine fever virus antigen proteins as an active ingredient, characterized in that,

however, when the combination of african swine fever virus antigen proteins includes lectin protein and CD2v protein, the combination of african swine fever virus antigen proteins is composed of three or more antigen proteins.

11. A recombinant vector for expressing an antigenic protein of african swine fever virus, comprising: a polynucleotide encoding a p72 protein comprising the amino acid sequence of SEQ ID NO. 5; a polynucleotide encoding a p54 protein comprising the amino acid sequence of SEQ ID NO. 7; a polynucleotide encoding a p15 protein comprising the amino acid sequence of SEQ ID NO. 11; a polynucleotide encoding a p35 protein comprising the amino acid sequence of SEQ ID NO. 13; a polynucleotide encoding an E199L protein comprising the amino acid sequence of SEQ ID NO. 15; or a polynucleotide encoding an F317L protein comprising the amino acid sequence of SEQ ID NO. 17,

The recombinant vector is expressed in a plant body.

12. The recombinant vector for expressing an antigenic protein of African swine fever virus of claim 11,

the recombinant vector satisfies one or more characteristics selected from the group consisting of:

13. The recombinant vector for expressing an antigenic protein of African swine fever virus of claim 11,

the recombinant vector further comprises a polynucleotide encoding NB of SEQ ID NO. 19 or a polynucleotide encoding BiP of SEQ ID NO. 21.

14. The recombinant vector for expressing an antigenic protein of African swine fever virus of claim 13,

The polynucleotide encoding the NB or BiP is located in the 5' -end of the polynucleotide encoding the p72 protein, p54 protein, p15 protein, p35 protein, E199L protein or F317L protein.

15. The recombinant vector for expressing an antigenic protein of African swine fever virus of claim 11,

the recombinant vector further comprises a polynucleotide encoding the pFC2 fragment of SEQ ID NO. 27.

16. The recombinant vector for expressing an antigenic protein of African swine fever virus of claim 15,

the polynucleotide encoding the pFC2 fragment is located at the 3' -end of the polynucleotide encoding the p72 protein, the p54 protein, the p15 protein, the p35 protein, the E199L protein or the F317L protein.

17. The recombinant vector for expressing an antigenic protein of African swine fever virus of claim 11,

the recombinant vector further comprises a polynucleotide encoding an HDEL peptide of SEQ ID NO. 29.

18. The recombinant vector for expressing an antigenic protein of African swine fever virus of claim 17,

the polynucleotide encoding the HDEL peptide is located at the 3' -end of the polynucleotide encoding the p72 protein, the p54 protein, the p15 protein, the p35 protein, the E199L protein, or the F317L protein.

19. The recombinant vector for expressing an antigenic protein of African swine fever virus of claim 11,

the recombinant vector also comprises a polynucleotide encoding NB of SEQ ID NO. 19 or BiP of SEQ ID NO. 21; a polynucleotide encoding a pFC2 fragment of SEQ ID NO. 27; and a polynucleotide encoding an HDEL peptide of SEQ ID NO. 29.

20. The recombinant vector for expressing an antigenic protein of African swine fever virus of claim 19,

the recombinant vector is sequentially connected with polynucleotides for encoding NB or BiP;

polynucleotides encoding a p72 protein, a p54 protein, a p15 protein, a p35 protein, an E199L protein, or an F317L protein;

a polynucleotide encoding a pFc2 fragment; and

a polynucleotide encoding an HDEL peptide.

21. A transgenic organism, characterized in that,

transformed with the recombinant vector of any one of claims 11 to 20.

22. The transgenic organism of claim 21, wherein the transgenic organism is a plant,

the transgenic organism is a plant.

23. Use of the vaccine composition of claim 1 for the prevention of african swine fever.

24. Use of the vaccine composition of claim 1 in the preparation of a vaccine for the prevention of african swine fever.